It is incredible and bewildering!! (1) Stock goes up as approaching FDA decision. ABT contest contract prior to FDA Decision, (unusually and premature) stock down! (2) FDA approves Gralise, Stock up but not much due to ABT Dispute (uncertainty, e.g. SVNT), Orphan Drug Status issue brought forward soon after, stock down! (Again, unusual action by FDA) (3) ABT Dispute settled, Gralise rights retained by Depo, 40 Million payment, CP pulling all together, hit double digits, then, CP resigns (personal reasons – Yep Right!!!), stock down, even down to 7's. What else can happen?
The only risk here is an expensive launch that goes poorly.
Given the companies past success using contract salesforce I see that risk as minimal (but still there), upside of course is at this price Gralise and Serada are both essentially free-if either starts to look like even a sub-blockbuster there will be massive PPS appreciation here.